Table 2 Outcomes of clinical trials of featured novel agents and treatment combinations in AML from ASH 2022
From: Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting
Drug | Indication | ORR | CRc | Notable side effects | References |
|---|---|---|---|---|---|
Magrolimab | ND AML | 81% | 72% | Anemia, infusion reactions | [6] |
Gilteritinib | ND and R/R AML | 100% (ND) 70% (R/R) | 92% (ND) 20% (R/R) | Infection | [7] |
SNDX-5613 (Revumenib) | R/R AML | 53% | 38% | Differentiation syndrome | [3] |
KO-539 (Ziftomenib) | R/R AML | 40% | 35% | Differentiation syndrome, pneumonitis | [4] |
Pivekimab sunirine (PVEK) | R/R AML | 45% | 25% | Infusion reactions | [5] |